Allergan receives new MHRA approval for Botox

Allergan has announced that its drug Botox has been approved in a new indication by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

The product has been ratified for the treatment of ankle disability due to lower limb spasticity associated with stroke in adults, a decision that means Botox has now been approved in 12 indications in the UK.

It becomes the first and only neuromodulator to be approved specifically for the treatment of both upper and lower limb spasticity in adults who have had a stroke. Studies have shown that Botox can significantly improve muscle tone among patients in this group.

Spasticity is one of the most common long-term consequences of stroke and can often lead to a significant loss of independence, affecting both the physical and emotional wellbeing of patients.

Martin Gillen, country manager at Allergan UK, said: "This approval recognises Allergan's longstanding commitment to innovation in post-stroke spasticity. With two approved indications in this field, Allergan continues to support doctors and their patients to better manage this potentially debilitating condition."

This comes after the MHRA approved the drug for use in the treatment of overactive bladder last year.